It is reported that Beijing Yixun Medical Technology Co., Ltd. (referred to as “Yixus Medical â€), which focuses on the accurate use of chronic diseases, has announced the completion of a new round of financing of tens of millions of yuan. This round is exclusively invested by Qifeng Medical. After the completion of the financing, Yixu Medical will further expand the team and market channels; and continue to increase investment in the research and development of genetic testing products and AI-assisted diagnosis and treatment technology.
According to public information, Yixu Medical was established in March 2016. It is a high-tech enterprise in Beijing Zhongguancun Life Science Park. The company has comprehensively carried out NGS gene sequencing services. Under the guidance of Prof. Hu Songnian from the Beijing Institute of Genomics of the Chinese Academy of Sciences, the company uses NGS sequencing. The company's own patented technology has designed and developed a genetically engineered gene sequencing product for hypertension, including genetic risk assessment of essential hypertension and related cardiovascular and cerebrovascular diseases, and more than forty types of hypertension and five major classes of drugs and related joints. The individual metabolic level of the drug.
Yixu Medical Co., Ltd. owns the core patent technology of NGS, aiming to create the industrial application of the “high blood pressure precision drug†gene detection kit and the feasibility of establishing a Chinese hypertension drug genome database.
Yixu Medical has a research team engaged in the development of high-throughput sequencing technology and bioinformatics big data analysis. Professor Hu Songnian, director of the State Key Laboratory of Beijing Genomics Institute of the Chinese Academy of Sciences, is the chief expert of pharmacogenomics in this project. The Department of Pharmacology, China Pharmaceutical University Professor Yang Jin is the chief expert of clinical quantitative pharmacology. Professor Liu Lihong, director of the Pharmaceutical Department of Beijing Chaoyang Hospital affiliated to Capital Medical University, is the chief expert of clinical individualized precision medication, aiming to further improve the industrial transformation ability of scientific research results in the field of chronic disease control. To jointly develop a group study of hypertension gene cohort and precision medication in China to improve the status of diagnosis and treatment of chronic disease groups in China.
Pet Massager,Cat Massage,Dog Massage,Pet Groomer Tools
Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizons.com